Bentham Science Logo

Track Your Manuscript:

Current Cancer Drug Targets

Volume 22, 11 Issues, 2022
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access

Call for Editors

Current Cancer Drug Targets is recruiting Editors in the following areas (and other important areas) of the Journal. If you are interested, then please submit your details for the Editor in Chief’s consideration below.

  1. AI/Drug Discovery
  2. Apoptosis
  3. Autophagy
  4. Cancer Nanomedicine and Target Drug Delivery
  5. Cancer Biomarker
  6. Cancer Genomics and Epigenetics
  7. Cancer Immunology and immunotherapy
  8. Cancer Signal Transduction
  9. Cancer Stem Cell
  10. Cancer Vaccines
  11. Chemoresistance
  12. Chemotherapy
  13. Childhood Cancer
  14. Clinical development of cancer drugs
  15. Covid and Cancer
  16. Emerging target for cancer drugs
  17. FDA Drug Approval Alert and Analysis
  18. Hepatocellular Carcinoma
  19. Health disparity in cancer medicine
  20. Monoclonal Antibodies
  21. Most common cancers (breast, lung, prostate, colon, etc.)
  22. Neuro-Oncology and Glioblastoma
  23. New trends in cancer drug discovery
  24. Oncogenes and Tumor Suppressor
  25. Preclinical development of cancer drug and IND/NDA filing
  26. Target Cancer Therapy
  27. Tumor Microbiome
  28. Tumor Microenvironment

* If you are willing to become an Editor, in any other section (not listed above), which you feel is relevant to Journals' scope, then please inform us by choosing the “Others” option from the drop down list when you are filling the form below.

  1. Editors are responsible to contribute 1 thematic issue each year in a their area of interest. We expect to receive thematic issue proposals from section editors within 4 months of their appointment, a list of potential authors (with a respectable h-index) within 6 months and the complete thematic issue within 9 months.
  2. Editors are also expected to occasionally solicit/contribute review articles.
  3. Promote the thematic issue amongst the research community to increase its visibility
Selection Criteria:

Selection by the Editor-in-Chief will be based on, but not limited to, the following factors:

  • Interested candidates must at least hold a Doctorate degree
  • A broad and extensive knowledge of the field
  • Previous editorial experience would be desirable

Editor Details

* These fields are mandatory.


Ruiwen Zhang
Center for Drug Discovery
University of Houston
Houston, TX
View Full Editorial Board

COPE Compliant

Cope Logo

Related Journals

Related eBooks

eBooks Catalog